Emilie Mas

Emilie Mas

Auto-generated profile, based on publicly available information

Emilie Mas

Adelaide Medical School, The University of Adelaide Faculty of Health and Medical Sciences, Adelaide, South Australia, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
ABAnne Barden
Anne Barden
MPMichael Phillips
Michael Phillips
LHLisa M. Hill
Lisa M. Hill
EFEvelyn M. Fletcher
Evelyn M. Fletcher
EMEmilie Mas
Emilie Mas
TCTomás B. Corcoran
Tomás B. Corcoran

3 November 2009 in Free Radical Research
Verified
Journal Article
Closed access
PDF file
EMEmilie Mas
Emilie Mas
ABAnne Barden
Anne Barden
TDThierry Durand
Thierry Durand
JGJean-Marie Galano
Jean-Marie Galano
KCKevin D. Croft
Kevin D. Croft
Trevor MoriTrevor Mori
Trevor Mori
Analysis of F2-isoprostanes in urine using gas chromatography-mass spectrometry is confounded by the presence of endogenous compounds interfering with the internal standard, 15-F2t-IsoP-d4 (m/z 573). Previous efforts to resolve the 15-F2t-IsoP-d4 from co-eluting peaks with different solid phase extractions were unsuccessful. This study has now used a highly-deuterated, d9-analogue of the derivatization agent N,O-Bis(trimethyl-d9-silyl) trifluoroacetamide (BSTFA-d9) yielding trimethylsilyl ethers, but this was not successful in resolving the 15-F2t-IsoP-d4 from co-eluting peaks. It was hypothesized that interfering peaks at m/z 573 could be the tetrahydro analogue of 15-F2t-IsoP. However, using an authentic standard showed the interfering peaks are not due to this metabolite. In subsequent experiments good resolution was shown of the 15-F2t-IsoP peak using 8-F2t-IsoP-d4 (m/z 573) as the internal standard. These data show that care must be taken when using GC-MS for quantitation of F2-IsoPs to prevent interfering substances affecting the results.

1 April 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
AMAustin G MILTON
Austin G MILTON
SLStephan Lau
Stephan Lau
KKKarlea L Kremer
Karlea L Kremer
SRSushma R Rao
Sushma R Rao
EMEmilie Mas
Emilie Mas
SKSimon A Koblar
Simon A Koblar
Introduction: Transient ischaemic attack (TIA) may be a warning sign of stroke and difficult to differentiate from minor stroke and TIA-mimics. Urgent evaluation and diagnosis is important as treating TIA early can prevent subsequent strokes. Recent improvements in mass spectrometer technology allow quantification of hundreds of plasma proteins and lipids, yielding large datasets that would benefit from different approaches including machine learning. Using plasma protein, lipid and radiological biomarkers, our study will develop predictive algorithms to distinguish TIA from minor stroke (positive control) and TIA-mimics (negative control). Analysis including machine learning employs more sophisticated modelling, allowing non-linear interactions, adapting to datasets and enabling development of multiple specialised test-panels for identification and differentiation. Methods and analysis: Patients attending the Emergency Department, Stroke Ward or TIA Clinic at the Royal Adelaide Hospital with TIA, minor stroke or TIA-like symptoms will be recruited consecutively by staff-alert for this prospective cohort study. Advanced neuroimaging will be performed for each participant, with images assessed independently by up to three expert neurologists. Venous blood samples will be collected within 48 hours of symptom onset. Plasma proteomic and lipid analysis will use advanced mass spectrometry (MS) techniques. Principal component analysis and hierarchical cluster analysis will be performed using MS software. Output files will be analysed for relative biomarker quantitative differences between the three groups. Differences will be assessed by linear regression, one-way analysis of variance, Kruskal-Wallis H-test, χ 2 test or Fisher’s exact test. Machine learning methods will also be applied including deep learning using neural networks. Ethics and dissemination: Patients will provide written informed consent to participate in this grant-funded study. The Central Adelaide Local Health Network Human Research Ethics Committee approved this study (HREC/18/CALHN/384; R20180618). Findings will be disseminated through peer-reviewed publication and conferences; data will be managed according to our Data Management Plan (DMP2020-00062).

18 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SBSerena Barnes
Serena Barnes
RKRoman Kostecki
Roman Kostecki
DSDeeksha Sharma
Deeksha Sharma
AMAustin G MILTON
Austin G MILTON
PTPaul Trim
Paul Trim
ENErik Noschka
Erik Noschka
Stroke is a major pathology, but current diagnostic methods are prone to misclassification with other neurological conditions, e.g., epilepsy or migraine, which delays proper treatment and carries a poorer prognosis. Development of accurate biomarkers to diagnose stroke events could decrease misidentification occurrence and promote appropriate, timely management. Lipid peroxidation products are generated under oxidative stress conditions and have previously been shown to increase in stroke patients. As the reference standard for lipid peroxidation, oxylipins could be biomarkers for acute ischemic cerebrovascular syndrome (AICS) events. Moreover, the ability to triage at-risk patients could expedite the necessary procedures required to conclusively diagnose AICS incidents. A label-free, in vivo oxidative status (IVOS) technology measuring carbonylation was also tested to determine efficacy as a point-of-care assessment tool. Potential AICS patients were independently clinically classified as transient ischaemic attack (TIA) or minor ischaemic stroke (grouped as AICS), or mimics per our published FAST-IT Protocol, including radiological assessment. Plasma oxylipins were quantified using liquid chromatography tandem mass spectrometry while carbonylation was determined with IVOS technology. Oxylipin and IVOS metrics from diagnostic groups were compared using respective, univariate linear regressions. Concentrations of 4(RS)-4-F4t-NeuroP fragment (oxylipin) and Mean Fluorescence (ARBU) detected by mass spectrometry or IVOS technology, respectively, were higher in AICS patients compared with mimics. This is the first study to investigate an early point-of-care assessment device combined with a panel of oxylipins to identify markers of oxidative stress associated with transient or minor ischemic stroke incidents to improve diagnostic differentiation of AICS patients from mimics.